# Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

> **NCT02639286** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 5 (actual)

## Conditions studied

- Lipodystrophy

## Interventions

- **DRUG:** ISIS 304801
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02639286
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-23
- **Primary completion:** 2019-09-26
- **Final completion:** 2019-09-26
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639286, "Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02639286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*